A Phase 1 Study of NM32-2668 (Anti-ROR1/Anti-CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

MC #24-01

NCT #
Condition(s)
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Molecular Target(s)
ROR1
Drug Classification(s)
Trispecific Antibodies
Agents(s)
NM32-2668
Phase(s)
I

Mechanism of Action

NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody

Purpose

  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from NM32-2668
  • How the study agent is acting on your body
  • If your body develops any antibodies against the study agent which could reduce the amount of the study agent in your blood and the effects of the study agent on your disease

Location

MCD

Similar Trials

Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Trispecific Antibodies
Yes
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
MCD
JIT-MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Lung Cancer (NSCLC), Pancreatic Cancer
MCD
JIT-MCLA-129-CL01
MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody
n/a
EGFR, MET
Esophageal Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC)
MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.